Navigation Links
Plexus Biomedical Inc. Gains FDA Approval of the First Medical Device to Help Prevent External Hemorrhoids During Vaginal Childbirth
Date:2/23/2011

OAKLAND, Tenn., Feb. 23, 2011 /PRNewswire/ -- Plexus Biomedical Inc. has been granted a new classification and approval from the Food and Drug Administration to market the first device clinically shown to help prevent external hemorrhoids during vaginal childbirth. Hemorrhoids associated with vaginal delivery are a frequent complication of childbirth and affect between 750,000 and 1,000,000 pregnant women in the U.S. every year.

The patented Hem-Avert® Perianal Stabilizer supports the perianal region of the patient during labor and delivery.  The unique device is easily applied, completely external and will soon be available to physicians and hospitals nationwide.

CEO David Blurton stated, "Since there were not any competitive products or predicate devices that addressed delivery-induced hemorrhoids, the company conducted a prospective, randomized, multicenter clinical study to provide the clinical data necessary for the FDA to create a new classification for the device through its de novo 510(k) process."

Findings from the clinical study showed that none of the women randomly chosen to use the Hem-Avert® device during labor and delivery developed hemorrhoids.  By contrast, 25% of the women in the control group who delivered without the Hem-Avert® device developed hemorrhoids as a direct result of vaginal delivery, a finding consistent with the reported incidence of hemorrhoids documented in medical literature.

The high incidence of delivery-induced hemorrhoids among all vaginal births yields a potential U.S. market in excess of $650M.  When combined with vaginal births from Canada and Europe, the potential market for the Hem-Avert® device doubles to $1.3B. The company believes better patient outcomes, cost savings, and patient demand will all contribute to the product's success.

Plexus Biomedical is dedicated to revolutionizing obstetrics by eliminating or reducing common problems and
'/>"/>

SOURCE Plexus Biomedical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations
2. BioMedical Enterprises, Inc. (BME) Introduces the HammerLock™ Shape Memory Device for Hammertoes.
3. Synapse Biomedical Receives FDA Humanitarian Use Device Designation for Amyotrophic Lateral Sclerosis (ALS)
4. DSM Biomedical to be Key Contributor at the Surfaces in Biomaterials Foundations 2010 BioInterface Symposium and Workshop
5. DuPont and DSM Announce Joint Venture in Surgical Biomedical Materials
6. ETC Biomedical Systems Offers New FDA Approved Hyperbaric Oxygen Therapy (HBOT) Medical Device
7. BINDER BIOMEDICAL, INC. Announces Official Launch of the NEWTON™ Intervertebral Body Fusion Spinal Spacer System
8. Crux Biomedical Named One of Top 50 Companies to Watch
9. Crux Biomedical Enrolls First Patient in Its Retrieve 2 U.S. Pivotal Trial
10. Drexel Biomedical Researchers Develop Device to Predict Diabetic Wound Healing
11. West Haven Firm Expands Biomedical Disposal Program with Community Economic Development Fund
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Revenue and earnings above the previous ... development In the past 2013/14 fiscal year (ended ... to EUR 4.287 billion (last year: EUR 4.190 billion) despite ... EUR 360 million. "Overall, 2013/14 was a successful fiscal year ... President and CEO of Carl Zeiss AG. "Thanks to our ...
(Date:12/17/2014)... , Dec. 17, 2014  Beamz Interactive, Inc. ... music products, today announced that it has signed ... manufacturer and supplier of innovative prosthetic, orthotic and ... part of the agreement, RSL Steeper will promote ... specifically configured for use within UK residential care ...
(Date:12/17/2014)... 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... of enrollment in its first Phase 2a study, ... confirmed the 1-month findings that were reported in ... - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... 1 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... obesity, today announced that the U.S. Food and Drug ... Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its ... is based on a substantial body of evidence gathered ...
... , IRVINE, Calif. , June 1 Cardiogenesis ... present at the Noble Financial Sixth Annual Equity Conference - ONTRACK ... Hollywood, Florida .  Executive Chairman Paul J. McCormick will ... at 5:00 pm Eastern Time ( 2:00 pm ...
Cached Medicine Technology:Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity 2Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity 3Cardiogenesis Corporation to Present at Noble Financial - ONTRACK 2010 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... cancers, especially leukemia, have improved greatly in the ... seem to face many health,and lifestyle challenges as ... and treatment methods, many continue to struggle with ... of life, according to a,study prepublished online in ...
... March 31 Hillenbrand,Industries, Inc. (NYSE: HB ) ... previously announced cash tender offer to purchase any,and all ... (CUSIP No.,431573AD6). The tender offer was made pursuant to ... to Purchase") and the related Letter of,Transmittal, which set ...
... 31 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... under which it may sell up to $50,million of ... a,24-month period. Alexza is not obligated to utilize any ... into and consummate other equity and,debt financing transactions., ...
... a Solid Foundation for Marriage and Family, ... offering an innovative program, "Supporting Healthy Marriage" to ... The purpose,of the program, administered by University Behavioral ... build a solid foundation,for marriage and family through ...
... to Consulting Addresses Fears That Lawyers Have That, ... Accurately Describes The Business, WASHINGTON, March 31 ... announced it is,becoming the first in the nation ... attorney. It had previously been the first in ...
... reduce lead dust during renovations , , MONDAY, March ... issued new rules designed to protect children from ... to homes and buildings. , Starting in ... standards" that are designed to reduce potential exposure ...
Cached Medicine News:Health News:Childhood Leukemia Survivors Struggle With Long-Term Comorbidities 2Health News:Childhood Leukemia Survivors Struggle With Long-Term Comorbidities 3Health News:Childhood Leukemia Survivors Struggle With Long-Term Comorbidities 4Health News:Hillenbrand Industries, Inc. Announces Expiration and Final Results of its Previously Announced 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces Expiration and Final Results of its Previously Announced 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 3Health News:Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. 2Health News:Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. 3Health News:Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. 4Health News:'Supporting Healthy Marriage' Program Offered by Montefiore 2Health News:Leventhal Weight Loss Incorporated Becomes First in the Nation Executive Weight Loss Consulting Service for Attorneys by an Attorney 2Health News:New Rule Seeks to Protect Kids From Lead Paint 2
... and value!, Comfortable feel and ... contoured handle , Finer control while ... action , Completely autoclavable for easy ... for recalibration , Easy-to-read precision micrometer ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
250L...
... ergonomics, and value!, Comfortable feel ... non-slip, contoured handle , Finer control ... spring action , Completely autoclavable for ... need for recalibration , Easy-to-read precision ...
Medicine Products: